The latest WaveLight® topographic-guided laser system in now available here in New York. Contoura is one of the most technologically advanced laser systems available in the United States to correct nearsightedness and nearsightedness with astigmatism. This state-of-the-art laser system was recently approved by the US Food and Drug Administration (FDA) for use in the United States.
FDA Study Results
- 92.6% of eyes achieved 20/20 vision or better
- 64.8% experienced 20/16 vision or better
- 34.4% could see 20/12.5 or better.
In FDA studies, Contoura technology produced the best results compared to previous FDA studies for myopia (nearsightedness) and myopic astigmatism (nearsightedness with astigmatism). In US-based clinical trials conducted by Alcon based in Fort Worth, Texas, a global leader in eye care and a division of Novartis, the results showed 12 months after surgery 92.6% of eyes that received topography-guided LASIK treatment achieved 20/20 vision or better, 64.8% experienced 20/16 vision or better, and 34.4% could see 20/12.5 or better. The study also showed a reduction in side effects that were sometimes associated with LASIK, including light sensitivity, difficulty driving at night, and glare.
Contoura Vision is performed using Alcon’s WaveLight EX500 excimer Laser Systems, combined with the WaveLight Topolyzer Vario Diagnostic Device. This laser is capable of capturing extremely detailed maps of the cornea, using 22,000 data points. This information is used to analyze aberrations and corneal abnormalities, allowing LASIK surgeons to perform a more personalized laser procedure, based on the unique corneal topography of the patient’s individual eye.